Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bastian

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Cancer Chemotherapy and Pharmacology|February 9, 2000
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal functionC Massari, S Brienza, M Rotarski, et al.
Cancer Letters|September 29, 1998
Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapyY Canitrot, F Bichat, S P Cole, et al.
Bulletin Du Cancer|January 1, 1986
[Phase II trial of an ambulatory treatment with 5-fluorouracil administered by continuous perfusion combined with vindesine and cyclophosphamide]T Palangie, G Bastian, C Demarcq, et al.
Oncology (Williston Park, N.Y.)|December 1, 2000
Impact of UFT on tumoral TS and DPD levels in colorectal cancerG Bastian, J F Seitz, V Moutardier, et al.
Clinical Pharmacology and Therapeutics|August 1, 1994
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancerG Metzger, C Massari, M C Etienne, et al.
International Journal of Cancer|March 12, 1992
Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cellsM T Dimanche-Boitrel, H Pelletier, P Genne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 1998
Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trialR Stupp, J Bauer, O Pagani, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracilL Thiberville, P Compagnon, N Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessmentF Saliba, R Hagipantelli, J L Misset, et al.
Applied Optics|July 12, 2013
Terahertz plastic compound lensesM Wichmann, A S Mondol, N Kocic, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|February 9, 2000
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal functionC Massari, S Brienza, M Rotarski, et al.
Cancer Letters|September 29, 1998
Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapyY Canitrot, F Bichat, S P Cole, et al.
Bulletin Du Cancer|January 1, 1986
[Phase II trial of an ambulatory treatment with 5-fluorouracil administered by continuous perfusion combined with vindesine and cyclophosphamide]T Palangie, G Bastian, C Demarcq, et al.
Oncology (Williston Park, N.Y.)|December 1, 2000
Impact of UFT on tumoral TS and DPD levels in colorectal cancerG Bastian, J F Seitz, V Moutardier, et al.
Clinical Pharmacology and Therapeutics|August 1, 1994
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancerG Metzger, C Massari, M C Etienne, et al.
International Journal of Cancer|March 12, 1992
Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cellsM T Dimanche-Boitrel, H Pelletier, P Genne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 1998
Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trialR Stupp, J Bauer, O Pagani, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracilL Thiberville, P Compagnon, N Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessmentF Saliba, R Hagipantelli, J L Misset, et al.
Applied Optics|July 12, 2013
Terahertz plastic compound lensesM Wichmann, A S Mondol, N Kocic, et al.
Pageof 5